Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

British Journal of Haematology

Volumn 139, Issue 3, 2007, Pages 425-428

  O'Connor, Owen A ^a,b   Hamlin, Paul A ^b   Portlock, Carol ^b   Moskowitz, Craig H ^b   Noy, Ariela ^b   Straus, David J ^b   MacGregor Cortelli, Barbara ^b   Neylon, Ellen ^b   Sarasohn, Debra ^b   Dumetrescu, Otila ^b   Mould, Diane R ^b   Fleischer, Martin ^c   Zelenetz, Andrew D ^b   Sirotnak, Frank ^b   Horwitz, Steven ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Projections Research Inc   (United States)

Author keywords

Antifolate; Pralatrexate; Reduced folate carrier; T cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PRALATREXATE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SKIN DEFECT; T CELL LYMPHOMA;

ADULT; AGED; AMINOPTERIN; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 34848829782     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06658.x     Document Type: Article

References (12)

1. Devesa, S.S. Fears, T. (1992) Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Research, 52 (Suppl. 19 5432s 5440s.
2. Gisselbrecht, C., Gaulard, P., Lepage, E., Coifier, B., Briere, J., Haioun, C., Cazals-Hatem, D., Bosly, A., Xerri, L., Tilly, h., Berger, F., Bouhaabdallah, R. Diebold, J. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood, 92, 76 82.
3. Krug, L.M., Ng, K.K., Kris, M.G., Miller, V.A., Tong, W., Heelan, R.T., Leon, L., Kelly, J., Grant, S.C. Sirotnak, F.M. (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clinical Cancer Research, 6, 3493 3498.
4. Krug, L.M., Azzoli, C.G., Kris, M.G., Miller, V.A., Khokhar, N.Z., Tong, W., Ginsberg, M.S., Venkatraman, E., Tyson, L., Pizzo, B., Baez, V., Ng, K.K. Sirotnak, F.M. (2003) 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clinical Cancer Ressearch, 9, 2072 2078.
5. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. Linet, M.S. (2005) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 265 276.
6. O'Connor, O.A. (2005) Developing new drugs for the treatment of lymphoma. European Journal of Haematology Supplementum, 75 (Suppl. 66 150 158.
7. Rudiger, T., Weisenburger, D.D., Anderson, J.R., Arimitage, J.O., Diebold, J., MacLennan, K.A., Nathwani, B.N., Ullrich, F. Muller-Hermelink, H.K. Non-hodgkin's Lymphoma Classificatio Project. (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology, 13, 140 149.
8. Sirotnak, F.M., DeGraw, J.I., Schmid, F.A., Goutas, L.J. Moccio, D.M. (1984a) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemotherapy and Pharmacology, 12, 26 30.
9. Sirotnak, F.M., DeGraw, J.I., Moccio, D.M., Samuels, L.L. Goutas, L.J. (1984b) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemotherapy and Pharmacology, 12, 18 25.
10. Sirotnak, F.M., DeGraw, J.I., Colwell, W.T. Piper, J.R. (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemotherapy and Pharmacology, 42, 313 318.
11. Toner, L., Vrhovac, R., Smith, E., Gardner, J., Heaney, M., Teruya-Feldstein, J., Sirotnak, F. O'Connor, O.A. (2006) The schedule dependent effects of the novel antifolate 10-propargyl-10dezaminopterin (PDX) and gemcitabine are markedly superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clinical Cancer Research, 123, 924 932.
12. Wang, E.S., O'Connor, O.A., Zelenetz, A. Moore, M. (2003) Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leukemia and Lymphoma, 44, 1027 1035.